GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinogen Medical Ltd (FRA:3AC) » Definitions » Long-Term Capital Lease Obligation

Actinogen Medical (FRA:3AC) Long-Term Capital Lease Obligation : €0.00 Mil (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Actinogen Medical Long-Term Capital Lease Obligation?

Actinogen Medical's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil.

Actinogen Medical's annual Long-Term Capital Lease Obligation declined from Jun. 2022 (€0.06 Mil) to Jun. 2023 (€0.00 Mil) but then increased from Jun. 2023 (€0.00 Mil) to Jun. 2024 (€0.16 Mil).


Actinogen Medical Long-Term Capital Lease Obligation Historical Data

The historical data trend for Actinogen Medical's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actinogen Medical Long-Term Capital Lease Obligation Chart

Actinogen Medical Annual Data
Trend Jun14 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.19 0.11 0.06 - 0.16

Actinogen Medical Semi-Annual Data
Jun14 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 - - - 0.16

Actinogen Medical  (FRA:3AC) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Actinogen Medical Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Actinogen Medical's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Actinogen Medical Business Description

Industry
Traded in Other Exchanges
Address
109 Pitt Street, Level 9, Suite 901, Sydney, NSW, AUS, 2000
Actinogen Medical Ltd is a biotechnology company. The company develops drugs for Alzheimer's disease and the cognitive decline associated with other neurological diseases. It is focused on the clinical development of Xanamem, an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Geographically, the company's income is derived in Australia.

Actinogen Medical Headlines

No Headlines